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ABSTRACT 
Physical disruption of atherosclerotic plaques causes many acute thrombotic complications such as myocardial 
infarction and stroke. The resistance of the atherosclerotic plaque to disruption depends in part on the integrity 
of its fibrous cap, which prevents contact between the highly thrombogenic lipid core and the circulating blood. 
The fibrillar collagens types I and III synthesized by smooth muscle cells (SMCs) largely determine the tensile 
strength of the cap.  
 
Sites of plaque rupture display signs of active inflammation that can impair plaque stability. Macrophages and 
mast cells release a set of collagen-degrading enzymes. Additional possible mechanisms include inhibited 
expression of procollagen genes and induction of death or reduced renewal of the collagen-producing SMC 
population, both phenomena promoted by T cell-derived interferon-γ (IFNγ). However, little attention has been 
given to the post-translational modification of collagen fibers in the fibrous caps. It is known that efficient 
extracellular cross-linking of collagen catalyzed by the enzyme lysyl oxidase (LOX) confers biomechanical 
properties and proteolytic resistance of the mature collagen fiber. Thus, failure of collagen maturation may lead 
to a defective extracellular matrix in the fibrous cap. 
 
Using atherosclerosis-prone mice and samples of human carotid endarterectomies, we investigated whether 
pro- and anti-inflammatory mediators can affect the LOX-dependent collagen maturation in atherosclerotic 
lesions, thus leading to plaque weakening. 
 
To study the effect of T cell-driven inflammation, we used genetically modified mice with 
hypercholesterolemia and disrupted TGFβ signaling in T cells (Apoe-/- x CD4dnTβRII). These mice developed 
larger atherosclerotic lesions with augmented levels of IFNγ, increased numbers of activated macrophages and, 
importantly, impaired maturation of collagen fibers, consistent with a vulnerable phenotype (Paper I). Analysis 
of mRNA and protein content showed a significant decrease of LOX in aortae of Apoe-/- x CD4dnTβRII mice. 
T cell-driven inflammation in these mice provoked a limited selective increase in the expression of proteinases 
that degrade the extracellular matrix, but no increase in collagen fragmentation was detected. Therefore, we 
concluded that exaggerated T cell-driven inflammation limits the extracellular maturation of collagen in the 
atherosclerotic plaque.   
 
The stability of atherosclerotic lesions was investigated in Apoe-/- mice after treatment with osteoprotegerin 
(OPG), a cytokine of the TNFR superfamily and a circulating decoy receptor for the receptor activator of 
nuclear factor B ligand (RANKL) (Paper II). Treatment with OPG facilitated accumulation of SMCs and 
increased formation of mature collagen fibers within the lesions of Apoe-/- mice. Aortic mRNA level of LOX 
was also upregulated in treated animals. In cell culture studies, OPG promoted proliferation of rat aortic SMCs. 
Therefore, we suggested that osteoprotegerin may be a possible mediator of lesion stabilization. 
 
We further investigated if a similar pattern as that obtained in the animal experiments could also be found in 
the human disease (Paper III). We were able to detect LOX protein in SMC- and collagen-rich areas of human 
carotid lesions. A higher LOX mRNA and protein were associated with a more stable phenotype of the 
plaques. Examination of gene expression in plaques revealed a positive correlation between mRNA expression 
of LOX and mRNA for OPG, and a negative correlation between LOX mRNA and markers of inflammation. 
This data suggests that LOX may contribute to the stabilization of human atherosclerotic lesions and that its 
expression is controlled by inflammation. 
 
In paper IV we reported that mRNA and protein content of 5-lipoxygenase activating protein (FLAP) were 
highly upregulated in aortae of Apoe-/- x CD4dnTβRII mice compared with Apoe-/- littermates. FLAP 
immunoreactive protein co-localized with CD68+ macrophages. Augmented ex vivo formation of leukotriene 
B4 in aortae of transgenic mice further supported functional significance of the increased level of FLAP. 
Treatment with the FLAP-inhibitor MK-886 not only decreased the number of CD3+ cells in lesions and IFN 
mRNA levels in aortae of Apoe-/- x CD4dnTβRII mice, but, most importantly, significantly reduced 
atherosclerotic lesion size. Although FLAP inhibition did not have any significant effect on collagen synthesis, 
it can be considered as a possible therapeutic tool to stabilize the plaque by reducing the degree of local 
inflammation. 
 
In summary, the findings of this thesis identify extracellular maturation of collagen, catalyzed by LOX, as 
important in maintaining the stability of the fibrous cap in the atherosclerotic lesion. The process of collagen 
maturation is regulated by pro- and anti-inflammatory mediators within the plaque, and it may serve as a target 
for development of new diagnostic and therapeutic tools. 
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The world makes way for those who know 
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3 INTRODUCTION 
Cardiovascular diseases and specifically atherosclerosis are among the main causes of 
death globally [1, 2]. Atherosclerosis is responsible for ischemic heart disease, ischemic 
stroke and critical limb ischemia. An atherosclerotic plaque causes progressive luminal 
narrowing and results in stable clinical manifestations of atherosclerosis. On the other 
hand, thrombus formation on the plaque surface leads to acute and lethal clinical 
manifestations of atherosclerosis such as unstable angina, myocardial infarction and 
stroke. The incidence of atherosclerotic complications increases globally forcing 
scientists to look for new strategies for prediction, prevention, and treatment [3].   
An atherosclerotic lesion (atheromata) is an eccentric focal thickening of the intima, the 
innermost layer of the artery [1]. It results from a complex interaction between blood 
elements, disturbed flow and vessel wall abnormalities. Consecutive pathological 
processes in the intima lead to plaque growth initiation, progression and complications. 
Such processes include (a) lipid retention and accumulation in the subendothelial space; 
(b) inflammation with increased endothelial permeability, endothelial activation and 
immune cell recruitment; (c) growth with smooth muscle cell (SMCs) proliferation, 
migration and matrix synthesis; (d) degeneration and necrosis with debris 
accumulation; (e) calcification; and (f) thrombosis with platelet recruitment and fibrin 
formation [1]. 
Mature atherosclerotic plaques (types IV and Va according to the classification of 
American Heart Association [4]) typically consist of two main components: a soft lipid 
core and a fibrous cap which separates the core from the lumen [5]. The stability of the 
atherosclerotic plaque and its resistance to disruption depend in part on the integrity of 
the fibrous cap that is composed of SMCs and a collagen-rich extracellular matrix 
(Figure 1). An inverse relationship has been demonstrated between cap thickness and 
peak circumferential stress in the plaque [6]. The extracellular matrix content, and 
particularly fibrillar collagens types I and III synthesized by SMCs, usually determine 
the stability and strength of tissues, including arteries. Collagen can tolerate much 
greater tensile stress than elastin [7]. Therefore, collagen-poor fibrous caps are more 
fragile. 
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The most frequent pathoanatomical substrate for sudden arterial thrombosis is a 
physical disruption of the fibrous cap and exposure of the highly thrombogenic lipid 
core to factors of blood coagulation [5, 8]. Pathologists have identified a number of 
characteristics of atherosclerotic plaques that caused fatal thrombi. These unstable 
plaques, contain large lipid cores and thin fibrous caps (<65µm), and are infiltrated 
with activated immune cells such as macrophages and T cells  [1, 9]. Inflammatory 
cells can influence the function of SMCs and collagen strength within the fibrous cap 
by producing pro-inflammatory cytokines, proteases, coagulation factors, radicals, and 
vasoactive molecules [1]. Loss of SMCs and altered collagen metabolism can lead to 
thinning of the collagen-rich fibrous cap and hence to its destruction [9].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Human carotid plaque stained for -actin positive SMCs. The fibrous cap is denoted 
by head arrows: filled arrow head – SMC-rich region; empty arrow head – SMC-poor region 
of the cap. Original magnification x10.   
 
Ample scientific literature of the past two decades strongly suggests that a disbalance 
between collagen synthesis and degradation is the main cause of collagen loss from the 
fibrous cap [1, 9]. Based on numerous in vitro and in vivo studies, it is now believed 
that collagen gene expression can be hampered by cytokines that are produced in 
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activated T cells [10, 11], whereas mature collagen fibers in the fibrous cap can be 
degraded by macrophage-derived proteolytic enzymes [7, 9, 12].   
Little attention has been paid to changes in the maturation of collagen in determining 
plaque stability. The tensile strength of collagen and its resistance to proteolytic 
enzymes largely depend on the efficiency of intramolecular and intermolecular cross-
linking generated in a complex multistep process of collagen maturation [13]. 
However, it is still unclear if fragile plaques have a low concentration of mature 
collagen cross-links. 
Therefore, we focused our investigations on the mechanisms involved in collagen 
maturation within the atherosclerotic lesion and on the effect of pro- and anti-
inflammatory stimuli on the efficiency of collagen cross-linking in the fibrous cap.  
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4 COLLAGENS IN ATHEROSCLEROSIS 
Members of the collagen family are the most abundant proteins in the extracellular 
matrix and are the major structural elements of all connective tissues. Collagens 
contribute to stability and maintain structural integrity of tissues and organs including 
the vasculature.  
 
4.1 COLLAGEN TYPES AND THEIR BASIC STRUCTURE  
28 genetically distinct collagen types have been described so far. They are divided into 
several groups based on their structure and supramolecular organization (Table 1) [13, 
14]. Fibril-forming (fibrillar) collagens are the most abundant and wide-spread family. 
Their torsional stability and tensile strength provide mechanical stability of tissues.     
All members of the collagen family have one characteristic feature in common: they are 
composed of three -chains organized in a right-handed triple helix (Figure 2). The 
triple helix can be formed by three identical chains (homotrimers) as in collagens type 
II, III, VII, and X, or by two or more different chains (heterotrimers) as in collagens 
type I, IV, V, VI, IX, and XI. A structural basis for the triple helical assembly is a 
presence of glycine, the smallest amino acid, in every third position of the polypeptide 
chain – (Gly-X-Y)n. The -chains assemble so that all glycyl residues are positioned in 
the center of the triple helix (Figure 2). This configuration allows a close packing along 
the central axis of the triple helix [13]. In the triplet, X is often a proline, and Y is 
frequently a hydroxyproline (Figure 2).  
In the intracellular space the procollagen monomer is flanked by N- and C-propeptides 
that have important functions in procollagen processing. The C-propeptide plays a 
fundamental role in the initiation of triple helix formation, and the N-propeptide is 
thought to be involved in the regulation of the primary fibril diameter (Figure 2).   
The processed collagens consist of a central triple helical region (collagenous domain) 
and two non-helical regions called telopeptides at the N- and C-terminal. Triple helical 
regions form domains of 300 nm in length (about 1000 amino acids) as in fibril-
forming collagen, or contain much shorter domains alternating with non-triple helical 
interruptions like in other collagen types [13, 14].  
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Table 1. The various collagen types and respective major collagen families (modified 
after [13]). 
Type Molecular composition Genes (genomic localization) Tissue distribution 
 
Fibril-forming (fibrillar) collagens 
 
I 1(I)2 2(I)  COL1A1 (17q21.31-q22) 
COL1A2 (7q22.1) 
Bone, dermis, vessel wall, tendon, ligaments, 
cornea 
II 1(II)3 COL2A1 (12q13.11-q13.2) Cartilage, vitreous body, nucleus pulposus 
III 1(III)3 COL3A1 (2q31) Skin, vessel wall, reticular fibers of most tissues 
(lungs, liver, spleen, etc) 
V 1(V),2(V), 3(V) COL5A1 (9q34.2-q34.3) 
COL5A2(2q31) 
COL5A3 (19p13.2) 
Lungs, cornea, bone, fetal membranes; together 
with collagen type I 
XI 1(XI),2(XI), 3(XI) COL11A1(1p21) 
COL11A2 (6p21.3) 
COL11A3 = COL2A1 
Cartilage, vitreous body 
 
Basement membrane collagens 
 
IV 1(IV)2 2(IV); 1-6 COL4A1 (13q34) 
COL4A2 (13q34) 
COL4A3 (2q36-q37) 
COL4A4 (2q36-q37) 
COL4A5 (Xq22.3) 
COL4A6 (Xq22.3) 
Basement membranes 
 
Microfibrillar collagens 
 
VI 1(VI),2(VI), 3(VI) COL6A1 (21q22.3) 
COL6A2 (21q22.3) 
COL6A3 (2q37) 
Widespread: dermis, cartilage, placenta, lungs, 
vessel wall, intervertebral disc 
 
Anchoring fibrils 
 
VII 1(VII)3 COL7A1 (3p21.3) Skin, dermal-epidermal junctions; oral mucosa, 
cervix 
 
Hexagonal network-forming collagens 
 
VIII 1(VIII)2 2(VIII) COL8A1 (3q12-q13.1) 
COL8A2 (1p34.3-p32.3) 
Vessel wall, Descemet’s membrane 
X 1(X)3 COL10A1 (6q21-q22.3) Hypertrophic cartilage 
 
FACIT collagens 
IX 1(IX),2(IX), 3(IX) COL9A1 (6q13) 
COL9A2 (1p33-p32.2) 
Cartilage, vitreous humor, cornea 
XII 1(XII)3 COL12A1 (6q12-q13) Perichondrium, ligaments, tendon 
XIV 1(XIV)3 COL14A1 (8q23) Dermis, tendon, vessel wall, placenta, lungs, 
liver 
XIX 1(XIX)3 COL19A1 (6q12-q14) Human rhabdomyosarcoma 
XX 1(XX)3 COL20A1 (20q13.33) Corneal epithelium, embryonic skin, sterna 
cartilage, tendon 
XXI 1(XXI)3 COL21A1 (6q12.3-11.2) Vessel wall 
 
Transmembrane collagens 
 
XIII 1(XIII)3 COL13A1 (10q22) Epidermis, hair follicle, endomysium, intestine, 
chondrocytes, lungs, liver 
XVII 1(XVII)3 COL17A1 (10q24.3) Dermal – epidermal junctions 
 
Multiplexins  
 
XV 1(XV)3 COL15A1 (9q21-q22) Fibroblasts, SMCs, kidney, pancreas 
XVI 1(XVI)3 COL16A1 (1p34) Fibroblasts, amnion, keratinocytes 
XVIII 1(XVIII)3 COL18A1 (21q22.3) Lungs, liver 
Figure 2. Schematic presentation of collagen type I structure and synthesis. (1), collagen 
translation in the rough endoplasmic reticulum and hydroxylation of prolyl and lysyl residues 
with prolyl-4-hydroxylase (P4H) and lysyl hydroxylase (LH); (2), triple helix assembly from 
C-terminal; (3), transport in vesicles and secretion; (4), cleavage of C- and N-propeptides; 
(5), oxidation of lysyl and hydroxylysyl residues in telopeptides; (6), Amadori rearrangement 
of immature links and formation of mature non-reducible cross-links, HP – 
hydroxylysylpyridinoline (as an example); (7), organization of collagen fibrils in the 
characteristic quarter-staggered manner and the scheme of “banded fibrils” appearance of 
collagen on electron micrographs.    
C-terminal 
C-propeptide N-propeptide 
OH 
OH 
OH 
OH 
telopeptide telopeptide 
Triple helix 
OH 
OH OH 
LH2 
P4H 
LH1 
Rough endoplasmic reticulum 
Plasma membrane 
NH2 
OH O 
H2O2
 
300nm 
40nm Monomer 
LOX 
C-propeptidase 
N-propeptidase 4 
5 
6 
OH NH2 
Glycine 
Proline 
Lysine 
Procollagen  
1-chain (I) 
Procollagen  
2-chain (I) 
7 
67nm 
OH 
OH 
OH 
HP 
Mature  
cross-link 
1 
2 
3 
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Collagen type IV with a flexible triple helix makes a three-dimensional structure to 
form basement membranes. Collagenous domains of collagen type VI yield the 
ultrastructural appearance of beads on a string through formation of dimers and 
tetramers [13, 14].  
The short non-helical telopeptides of the processed collagen monomers are involved in 
the covalent cross-linking of fibrils in the extracellular space. They also help linking 
collagen to other molecular structures of the surrounding matrix [13, 14]. In the 
extracellular space, collagen fibrils are aligned and assembled in the generally accepted 
quarter-stagger model [15]. On electron micrographs, fibrils appear as an alternating 
light and dark pattern, which gives them a name “banded fibrils” (Figure 2) [14]. 
 
  
4.2 COLLAGEN LOCALIZATION IN ATHEROSCLEROTIC LESIONS 
Collagen is the major extracellular component of atherosclerotic plaques. Collagen type 
I and III together represent approximately 60% of the total protein content and at least 
90% of the total collagen content of the plaque [16-18]. Other collagens frequently 
detected in the atherosclerotic lesion are collagen type IV, V, VI and VIII [17, 19].  
The localization of collagens in atherosclerotic plaques varies at different stages of the 
disease [17]. Collagens type I and III are diffusely co-distributed in the thickened 
intima at all stages during plaque progression [16, 17, 20]. Their mRNA expression is 
significantly increased in atherosclerotic plaques compared with underlying media or 
intima of the normal artery both in humans and in animals [21-24]. In the advanced and 
complicated lesions, collagens type I and III are mostly present in the fibrous cap but 
not in the lipid core [16, 17, 20, 24]. The distribution of these two collagens in the 
fibrous cap varies resulting in collagen deficient regions and collagen-rich regions [20, 
24]. 
Collagen type IV is present in the subendothelium of the normal intima where it forms 
the endothelial basement membrane. Collagen type IV occurs also in the basal lamina 
of the SMCs [17, 18], and its deposits can be observed in calcified tissues and in small 
new vessels of advanced lesions [17]. 
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Collagens type V and VI are not detected in the intima of normal vessels or in early 
lesions, whereas their content increases with lesion progression. Both collagen types 
appear together with collagens type I and III in later stages of lesion development [17]. 
Collagen type V is located in the subendothelium and associated with SMC surface; 
collagen type VI is found between collagen type I fibers in the media and in the 
subendothelium [18].  
Collagen VIII is widely distributed in the vessel wall and can be secreted by monocytes 
and macrophages as well as by SMCs [25, 26]. It has been detected in all three layers of 
the normal vessel wall and depositions of collagen type VIII have been observed in 
atherosclerotic lesions at early stages of development. In advanced lesions, it is 
deposited together with fibrillar collagens in the fibrous cap, the plaque shoulders and 
the plaque base [19].    
Sparse or no collagen can be detected in the lipid core of advanced atheromatas [17].  
 
 
4.3 COLLAGEN FUNCTIONS IN ATHEROSCLEROSIS 
The role of collagen in atherogenesis is rather diverse. At some stages of the disease 
collagen can be considered an enemy, and at some stages – a friend. At later stages of 
atherogenesis collagen provides the tensile strength of the intima and guards against 
fibrous cap rupture [9, 27]. However, collagen can also promote plaque growth by 
stimulating cell migration and providing permissive matrix for lipid retention [18, 27]. 
 
4.3.1 Collagen functions in plaque progression 
SMCs in the atherosclerotic plaque can migrate, divide and synthesize extracellular 
matrix in response to mechanical or chemical (cytokines and growth factors) 
influences. These SMCs have the synthetic phenotype and are regarded as poorly 
differentiated in contrast to the contractile phenotype of SMCs in the media [28, 29]. 
SMCs cultured from atherosclerotic lesions secrete more collagen compared with the 
cells isolated from regions of normal arteries [30, 31]. Newly synthesized collagen 
contributes to the thickening of the vessel wall and, together with the cellular 
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components, is responsible for the occlusion of the vessel lumen caused by the growing 
atherosclerotic plaque [18].  
Apart from the space-filling role, collagen provides an anchorage for cells and exerts an 
important influence on their phenotype and behavior through receptor-mediated 
contacts. The principal collagen binding receptors that are expressed on SMCs include 
integrins (11, 21, 31, v3) and the discoidin domain receptor (DDR1 and 
DDR2) tyrosine kinases [27]. In vitro experiments have shown that integrins bind both 
native and heat-denatured collagen [27, 32]. DDRs are expressed in atherosclerotic 
plaques and can be activated only by collagen in its native, triple-helical form [33, 34]. 
Collagens may also modulate cell function indirectly by acting as binding sites for 
other matrix components such as thrombospondin, von Willebrand factor, and 
fibronectin [18]. 
Collagens are believed to be critical regulators of SMC phenotype alterations, 
proliferation and migration in the atherosclerotic plaque via integrin-mediated 
pathways [18, 27, 35, 36]. The polymerization state of collagen is an important 
determinant of this aspect. SMCs proliferate and move faster when plated on 
monomeric collagen compared with collagen fibers [18, 27]. The monomeric collagen 
induces the expression of many genes that are important in regulation of cells 
spreading, whereas polymerized collagen type I acts as a suppressive agent [27, 37]. 
Newly synthesized or degraded collagen is also an important matrix for cell migration. 
Treatment of cultured cells with inhibitors of collagen synthesis or collagenolysis 
attenuates SMC migration and invasion [38-40].  
The same observations have been made for collagen type IV. Soluble collagen IV 
added to the media can stimulate migration of cultured SMCs [27] whereas a mature 
collagen type IV net likely serves to maintain SMC quiescence by forming basement 
membranes around individual cells [29].  
The collagen-binding receptor DDR1 can also control the SMC response to injury. 
Ddr-/- SMCs exhibit reduced proliferation, migration and proteolytic activity in 
response to collagen type I in vitro [41], and overexpression of DDRs rescues these 
deficits [33, 42].  
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In addition to its influence on SMCs, collagen is capable of regulating phenotype and 
function of inflammatory cells present in the atherosclerotic plaques via activation of 
integrins, DDRs and class A scavenger receptors. Signals initiated by collagen-receptor 
interactions regulate all aspects of macrophage biology including differentiation, 
migration, production of inflammatory cytokines and elaboration of matrix degrading 
enzymes [43, 44]. Apolipoprotein E knockout (Apoe-/-) mice deficient also in the genes 
for integrin 1 and low density lipoproteins receptor knockout (Ldlr-/-) mice deficient 
also in DDR1 developed smaller plaques with a reduced content of macrophages and T 
cells [45, 46]. 
Finally, collagens may be important for binding and retention of native and oxidized 
low density lipoproteins (LDL) in the atherosclerotic plaque [47].  
 
4.3.2 Collagen functions in advanced plaques  
Major complications of atherosclerosis are caused by the fissuring or rupture of the 
fibrous cap. In advanced atherosclerotic lesions the distribution of collagen within the 
intima is not uniform. Generally speaking, fibrous caps are more collagen-rich than 
inner parts of the lesions [17]. Such fibrous cap localization of collagen in atheromata is 
of key clinical importance. Collagens fulfill a mechanical function providing tensile 
strength and playing an important role in maintaining plaque stability. Collagen type I 
modulates tensile strength of the vascular tissue, while collagen type III accounts for its 
elasticity [18].   
The protective role of collagens within the fibrous cap is unquestionable as long as the 
integrity of the atheromata surface is preserved. With rupture of the fibrous cap, 
circulating platelets come in contact with collagen fibers in the plaque. Collagen then 
interacts with platelet integrins, which may initiate coagulation and thrombus formation 
[18].  
Intimal calcification is a feature of advanced atherosclerotic lesions [48]. Mineral 
crystals can be deposited along collagen fibers. Furthermore, an exposure of aortic 
SMCs to collagen type I increases their mineralization and calcium incorporation [27, 
49].   
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4.3.3 Functions of other collagens in atherosclerosis 
Collagen type IV constitutes the general scaffold for the basement membrane and is 
involved in the process of cell adhesion [19, 50]. Its distribution around SMCs in 
atherosclerotic lesions suggests a relation to the morphological changes of SMCs from 
contractile to synthetic phenotype. The degree of collagen type IV expression can be an 
indicator of the prevailing SMC phenotype, because with thickening of the basement 
membrane SMCs decrease their proliferative capacity [17, 40]. Localization of collagen 
type IV around calcified tissue and neovessels suggests a possible involvement in the 
processes of calcification and neovascularization [17].    
It is believed that collagen type V can interact with collagen type I to regulate fibril 
diameter [51, 52]. Collagen type VI forms microfibrils and exhibits unique adhesive 
properties compared to other extracellular matrix components and cells. It is involved 
in the adhesion and activation of platelets and SMCs and can bind to various collagen 
types, heparin and von Willebrand factor [18, 19, 53, 54].  
Collagen type VIII stabilizes the vascular wall. It plays a role in uniting other 
components of the extracellular matrix, and can contribute to the elasticity of the vessel 
wall through interaction with the elastic system. Cellular and extracellular distribution 
of collagen type VIII in advanced atherosclerotic lesions may imply that it has a role in 
vascular repair and plaque stabilization [19]. 
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5 COLLAGEN METABOLISM IN ATHEROSCLEROSIS  
As mentioned earlier, the overall stability and flexibility of connective tissue depends 
on a basic framework of collagen fibers. Therefore, the strength and stability of 
collagen fibers are tightly regulated by the complex multistep processes of collagen 
biosynthesis and catabolism.  
The formation of mature fibrillar collagen involves many steps beyond gene 
transcription. Nascent procollagen polypeptides undergo a series of posttranslational 
modifications which include intracellular and extracellular steps (Figure 2). 
Intracellular processes of hydroxylation, glycosylation and self-association into triple 
helical structures are followed by extracellular cleavage of the N- and C-propeptides, 
cross-linking of side chains and self-aggregation into multimeric collagen fibers [13, 
55]. This multistep process requires three collagen hydroxylases, two collagen 
glycosyltransferases, two specific proteinases that cleave off the N- and C-propeptides 
and one specific oxidase that initiates cross-linking (Figure 2) [55]. Failure at any step 
of collagen biosynthesis results in fragile fibers that cannot withstand mechanical forces 
to the necessary extent and are more susceptible to proteolytic degradation. 
Additional mechanisms behind collagen fragility include an increase in extracellular 
non-enzymatic glycation- or oxidation-induced collagen cross-linking that occurs with 
ageing or in patients with diabetes. Non-enzymatic collagen cross-linking leads to 
formation of stiff and brittle collagen fibers [56].             
Mature collagen fibers can be efficiently degraded by at least two types of proteases: 
matrix metalloproteinases (MMPs) and cysteine proteases [9, 40, 57, 58]. 
This chapter will give an overview of the main steps of collagen metabolism with 
emphasis on the process of extracellular collagen cross-linking and the enzyme 
catalyzing this important extracellular step of collagen biosynthesis, lysyl oxidase 
(LOX). LOX-dependent collagen maturation in the atherosclerotic plaque has been the 
main focus of the work presented in the papers of this thesis.  
The biochemistry of proteolytic enzymes and their involvement in the process of 
atherosclerotic plaque destabilization have been a target of numerous investigations [9, 
40, 57, 58]. Therefore, only a brief overview of this process will be presented. 
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5.1 TRANSCRIPTION AND TRANSLATION 
All α-chains of various collagens are encoded by separate genes with a unique 
localization in the genome. Most collagen genes display a complex exon-intron pattern, 
ranging from 3 to 117 exons. The mRNA of -chain of fibrillar collagens can be 
encoded by more than 50 exons [13, 14].  
Different mRNA species can be generated by multiple transcription initiation sites, 
alternative splicing of exons or a combination of both. In addition to splicing, the pre-
mRNA undergoes capping at the 5’ end and polyadenylation at the 3’ end [13]. 
Ribosome-bound mRNA is translated into prepro-collagen chain that is transported to 
the lumen of the rough endoplasmic reticulum for further modifications [13]. 
  
5.2 INTRACELLULAR POSTTRANSLATIONAL MODIFICATION 
After removal of the signal peptide by a signal peptidase, prolyl and lysyl residues in 
the procollagen chains undergo hydroxylation by enzymes such as prolyl-3-
hydroxylase, prolyl-4-hydroxylase and lysyl hydroxylase (Figure 2). Such 
hydroxylation of residues in the primary procollagen sequence is a crucial step in the 
organization of the triple-helical structures. It also permits formation of intermolecular 
cross-links, which gives collagen fibers enormous tensile strength [59]. 
Conversion of proline to hydroxyproline is catalyzed by collagen prolyl-4-hydroxylase 
(P4H, Enzyme Commission number (EC №) 1.14.11.2), an 22 tetramer located 
within the lumen of the endoplasmic reticulum [60]. P4H has at least three isoenzymes 
in human. Each isoenzyme has a distinct -subunit that is bound to a protein disulfide 
isomerase (PDI). PDI serves as β-subunit for all three enzymes. P4H requires a set of 
co-factors that include Fe
2+
, 2-oxoglutarate, O2, and ascorbate [61]. In the fibril-
forming collagens, approximately 50% of the prolyl residues contain a hydroxyl group. 
In conditions of suboptimal activity of P4H, the underhydroxylated procollagen chains 
misfold and are either secreted from the cells at a slow rate or targeted for intracellular 
degradation [62, 63]. Reduction in the content of 4-hydroxyproline in secreted 
procollagen chain reduces the stability of fibers at physiological conditions [13, 64]. 
Moreover, the degree of proline hydroxylation affects collagen resistance to proteolytic 
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attacks [65, 66] and ability to recognize and bind other components of extracellular 
matrix [67].  
PDI has several functions such as (i) to catalyze the formation of intrachain and 
interchain disulfide bonds; (ii) to serve as the -subunit in collagen P4H; (iii) and to act 
as a chaperone that binds nascent procollagen chains and prevents their aggregation 
[55].  
The conversion of lysyl residues (Lys) to hydroxylysyl residues (Hyl) is catalyzed by 
enzyme lysyl hydroxylase (LH) (procollagen-lysine 2-oxoglutarate 5-dioxygenase, 
PLOD, EC № 1.14.11.4) in the endoplasmic reticulum. The enzyme has at least three 
isoenzymes (LH1, 2 and 3) [13, 55]. Hydroxylation of Lys can occur in the telopeptide 
regions in procollagen chains where it is catalyzed by LH2 (“telopeptide lysyl 
hydroxylase”, TLH), and in the triple helical part of the procollagen chain catalyzed by 
LH1 (“helical lysyl hydroxylase”, HLH) [56, 68]. Hydroxylation of Lys in the 
telopeptide region is a crucial step for the future enzymatic cross-link formation after 
procollagen secretion.  
Mutations in the human PLOD1 gene for LH1 results in Ehlers-Danlos syndrome 
characterized by generalized fragility of connective tissues [55]. Mice lacking the 
Plod1 gene develop aortic rupture due to abnormal morphology of collagen fibrils [69]. 
Mutations in the PLOD2 gene for LH2 that are identified in the patients with Bruck 
syndrome result in underhydroxylation of Lys in telopeptide regions, formation of 
aberrant cross-links and, thus, in bone fragility, scoliosis and osteoporosis [55]. On the 
other hand, the excessive hydroxylation of Lys in telopeptide regions by LH2 can result 
in adverse effects leading to excessive fibrogenesis [56, 68]. 
Hyl also represent sites for the attachment of sugar moieties by glucosyl transferases. 
These hydroxylated and glycosylated chains then self-assemble into helical trimers 
starting from the alignment of the C-terminal domains [13]. 
The efficient folding of the procollagen chains also depends on the presence of further 
enzymes: PPI (peptidyl-prolyl cis-trans-isomerase) and the collagen specific chaperone 
heat shock protein 47 (Hsp47) [13, 55].    
Hsp47 is a heat shock-inducible glycoprotein that is expressed selectively within the 
endoplasmic reticulum of cells that synthesize and secrete procollagen type I and III 
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[70]. A transient physical association between Hsp47 and procollagen within the 
endoplasmic reticulum serves to stabilize procollagen. It prevents premature 
aggregation of monomers into oligomeric forms and modulates their transfer to the 
Golgi apparatus before export from the cell [71]. Homozygous knockout of this gene in 
mice is lethal at the embryonic stage, indicating that this protein is essential for normal 
development [72].  
 
5.2.1 Intracellular modification of collagen in atherosclerotic 
lesions 
Information about the role of intracellular collagen modifying enzymes in atherogenesis 
is rather limited. The majority of studies have been done on animal models of 
atherosclerosis and showed that expression of enzymes accompanies the increase in 
collagen accumulation during early progression of the disease.  
SMCs from cholesterol-fed rabbits have increased mRNA level for the -subunit of 
P4H [73]. P4H enzymatic activity is increased in atherosclerotic lesions of various 
avian and animal models of atherosclerosis after exposure to common risk factors such 
as sympathetic nerve system activation and hyperlipidemia [74-76]. Expression of 
Hsp47 mRNA is induced in rat carotid arteries after balloon injury [77]. Hector et al 
demonstrated increased LH1 activity, as determined by higher concentration of Hyl, in 
human atherosclerotic plaques compared with underlying media [78]. All these 
observations of increased collagen synthesis support the notion that SMCs acquire 
synthetic phenotype at early stages of atherogenesis.  
On the other hand, it has been known for decades that the absence of vitamin C, a 
required co-factor for P4H, impairs formation of stable collagen and leads to fragility of 
blood vessels [79]. Apoe-/- mice that are unable to synthesize ascorbic acid have 
decreased collagen content in the lesions. This impairs the biomechanical strength of 
the plaques and makes them potentially vulnerable to rupture [80]. An increased 
amount of Hsp47 protein is detected in the SMC-rich fibrous cap of advanced lesions 
of Apoe-/- mice [81]. Moreover, studies on human atherosclerotic plaques 
demonstrated localization of α(III)-subunit of P4H and Hsp47 in the fibrous cap of 
advanced human carotid atherosclerotic lesions [82, 83]. Therefore, this limited data 
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suggests that efficient intracellular modification of collagen may determine plaque 
stability. 
 
5.3 SECRETION 
After processing and correct assembly into triple helices, procollagen is packed into 
secretory vesicles within the Golgi compartment and transported into the extracellular 
space. After secretion of procollagen, C- and N-propeptides are cleaved off by two 
specific proteases, the procollagen C-proteinase and the procollagen N-proteinase, 
respectively (Figure 2) [13].    
 
5.4 EXTRACELLULAR PROCESSING AND MODIFICATION  
Stabilization of newly formed and secreted collagen fibrils is achieved by the formation 
of covalent cross-links between neighboring collagen fibrils. Collagen cross-links can 
be divided into two types: enzymatic cross-links (LH- and LOX- mediated) and non-
enzymatic cross-links (advanced glycation endproducts (AGE) induced cross-links). 
   
5.4.1 Enzymatic collagen cross-linking. Lysyl oxidase 
The tensile properties of collagen fibers result from intermolecular cross-links that 
connect the nonhelical ends of two collagen monomers (telopeptides) with the triple 
helical part of the third adjacent monomer according to the quarter-stagger model 
(Figure 2) [15]. Each monomer of the fibril-forming collagens has four cross-linking 
sites: one in each telopeptide and two in the triple helical region, close to its N- and C-
terminal ends (Figure 2) [84]. The formation of collagen cross-links is a joint effort of 
two enzymes: the intracellular LH that was described earlier and the extracellular 
enzyme LOX. Excessive formation of enzymatic cross-links does not occur in 
physiological conditions due to tight control of the expression of LOX [56].  
The extracellular copper-dependent enzyme LOX initiates the formation of stable non-
reducible collagen cross-links by oxidizing specific Lys and Hyl in the telopeptide 
regions of collagen into aldehyde to give allysine and hydroxyallysine, respectively 
[56, 84, 85].  
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The stoichiometry of the reaction catalyzed by LOX is: 
 
RCH2NH2 + H2O + O2  RCHO + NH3 + H2O2  [85] 
 
This LOX-catalyzed step is important in the initiation of cross-link formation. Further 
aggregation of collagen fibrils into fibers occurs spontaneously. 
Cross-links that result from the hydroxyallysine pathway are more stable and 
predominate in connective tissues that bear large mechanical loads [84]. The 
hydroxyallysine in the telopeptide of one collagen monomer reacts with either a Lys or 
a Hyl in the triple helix on a neighboring monomer to give difunctional cross-links 
(ketoimine bonds). These immature cross-links further undergo Amadori rearrangement 
and then bind another Lys or Hyl in the telopeptide of third collagen monomer to form 
trifunctional non-reducible cross-links. These final mature Hyl-derived cross-links are 
hydroxylysylpyridinoline (HP), derived from three Hyl, and lysylpyridinoline (LP), 
derived from one Lys and two Hyl (Figure 2) [56, 68, 84]. HP cross-links are the most 
abundant and present in virtually all mature tissues including blood vessels [84, 86].  
 
5.4.1.1 The LOX enzyme 
LOX (protein-6-oxidase, EC № 1.4.3.13) is a copper amine oxidase that catalyzes the 
formation of covalent cross-links within collagen and elastin fibers [87]. It plays a 
central role in the repair of connective tissues all over the body including the 
cardiovascular system [84]. Decreased LOX activity is associated with disorganization 
of connective tissues as seen in copper transport disorders, such as cutis laxa and 
Menkes syndrome [87]. Lathyrism, a condition caused by toxic effects of Lathyrus 
odoratus seeds (sweet peas) that contain the irreversible LOX-inhibitor beta-
aminopropionitrile (BAPN), is characterized by abnormal collagen cross-linking due to 
inactivation of LOX [88]. Increased LOX activity is observed in several fibrotic 
conditions such as Alzheimer’s disease, proliferative retinopathy and heart failure [87, 
89-91].  
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LOX requires pyridoxal phosphate (vitamin B6) and tyrosyl-lysine quinone as essential 
co-factors [85]. Vitamin B6 deficiency in rats leads to a 25% decrease in enzymatic 
collagen cross-link formation in bones [92].  
LOX is expressed and secreted by vascular SMCs and other fibrogenic cells [87]. LOX 
protein is localized in the extracellular compartment of several tissues such as skin, 
aorta, heart, lung, liver and cartilage [85, 93, 94]. The catalytically active enzyme has 
also been documented within nuclei of vascular SMCs and fibroblasts [95], and, once 
secreted and proteolytically processed, mature LOX can translocate back to the nuclei 
of vascular SMCs [96].  
LOX is secreted from cells in the form of a catalytically inactive 50 kDa proenzyme 
(proLOX) which is proteolytically cleaved to yield the 32 kDa active enzyme (Figure 
3). This predominantly occurs in the extracellular space, although intracellular 
proteolytic processing cannot be excluded [97]. The propeptide is required for efficient 
secretion of proLOX, and for optimal activation of the LOX enzyme in the extracellular 
space [98]. Interestingly, the conversion of proLOX is catalyzed by the same enzyme 
that cleaves the C-terminal domain of the procollagen chain - the procollagen C-
proteinase (bone morphogenetic protein-1) [99, 100]. This represents a highly 
integrated mechanism for the formation of cross-linked collagen fibers. Other 
extracellular proteases can also cleave proLOX at the correct physiological site but with 
lower efficiency [100].    
The active LOX protein is insoluble in neutral saline which likely reflects its tight 
association with its substrates in the extracellular space, but the enzyme can be rapidly 
solubilized by buffers supplemented with 4 to 6 M urea [85, 97].  
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Figure 3. LOX structure and function. Modified from [101]. 
 
Thorough studies of the biochemistry of LOX have revealed that the substrate 
specificity of LOX is not restricted to elastin and collagen. Purified LOX oxidizes a 
number of basic, globular proteins with pI values > 8, such as histones and basic 
fibroblast growth factor, but does not oxidize neutral or acidic proteins [102-104]. 
There is evidence suggesting that exposure of cells to LOX increases intracellular 
endproducts of the reaction catalyzed by LOX, such as H2O2 [105]. This data suggests 
that additional LOX substrates are either intrinsic membrane proteins or proteins that 
are tightly bound to the cell surface. Moreover, the presence of LOX in the cytosolic 
and nuclear compartments may suggest that LOX can control cellular homeostasis [95, 
96]. Therefore, LOX might play a critical role in other biological processes beyond the 
oxidation of structural proteins and stabilization of the extracellular matrix. LOX has 
been implicated in regulation of tissue development, cell proliferation, intracellular 
signal responses, and cell migration. It can also act as either an antagonist or a 
protagonist of malignant processes [106].  
In vitro studies have suggested that LOX can be a potent chemoattractant. Purified 
active LOX is able to induce strong chemotactic responses in human monocytes and 
vascular SMCs [105, 107]. These responses are mediated by H2O2, the product of 
amine oxidation by LOX, which is markedly elevated in vascular SMCs upon exposure 
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to LOX. H2O2 induces changes in the content and architecture of cytoskeletal 
components and adhesive cell proteins, which results in directed cell migration [105]. 
Lucero et al [108] suggested that the chemotactic response of vascular SMCs to LOX 
can also be mediated via oxidation of cell surface proteins such as platelet-derived 
growth factor (PDGF) receptor-β to induce PDGF-induced chemotaxis.  
Another line of evidence suggests that LOX may affect the cell phenotype and play an 
important role in suppressing oncogenic cellular transformation [106, 109, 110]. LOX-
dependent cross-linking of matrix surrounding ductal breast carcinoma may represent a 
defense mechanism against invasion [111]. In contrast, it has been observed that LOX 
mRNA is upregulated in invasive breast cancer and that active LOX facilitates invasion 
by several lines of malignant cells via H2O2 production [106]. However, the detailed 
mechanisms involved in pro- and antioncogenic cellular responses to LOX are beyond 
the scope of the present work.  
The importance of translocation of active LOX into the nuclei and nuclear distribution 
of the enzyme is still unclear. However, given that histones 1 and 2 can be LOX 
substrates in vitro, it has been suggested that LOX activity within nuclei can be linked 
to the regulation of nuclear chromatin condensation and changes of the availability of 
promoter regions to transcriptional factors [106]. In line with this hypothesis, it has 
been shown that LOX can regulate mRNA expression of human collagen type III gene 
and elastin [112-114].      
It has to be noted that the 18 kDa propeptide (LOX-PP) that is enzymatically cleaved of 
the secreted proLOX has distinct functions in addition to preventing premature 
activation of LOX (Figure 3). LOX-PP has a unique structure and no sequence 
similarities to any other LOX-like proteins [93]. LOX-PP epitopes accumulate in 
injured arteries [115]. Synthetic LOX-PP can inhibit proliferation and TNF stimulated 
MMP-9 synthesis in cultured vascular SMCs [115].  
 
5.4.1.2 The LOX family 
In addition to LOX, at least four genetically distinct LOX-like (LOXL) proteins have 
been described: LOXL1, LOXL2, LOXL3 and LOXL4 [93]. All five proteins have 
related but different functions and carry a certain degree of homology. This makes them 
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one family that in turn is subdivided in two subfamilies (Table 2). The first LOX 
subfamily includes LOX and LOXL1 that bear the highest homology. They are 
secreted as proproteins that are proteolytically cleaved to release active enzymes. The 
members of the other subfamily (LOXL2, 3 and 4) contain four scavenger receptor 
cysteine-rich (SRCR) domains in the regions following the signal peptide, and as a 
result exist in stable, distinctly folded protein structures [106]. SRCR domains are 
known to mediate protein-protein interactions in cell adhesion and cell signaling [93].   
The pattern of expression of different members of the LOX family is partially 
overlapping (Table 2). However, LOX is responsible for 80% of lysyl oxidase activity 
in aortic SMCs, indicating that LOX is the main isoenzyme in these cells [116]. LOX, 
LOXL1, LOXL2 and LOXL3 proteins are all expressed in the cardiovascular system. 
LOXL2 is highly expressed in the fetal heart, and LOXL3 expression is restricted to the 
adult aorta [117].   
All members of the LOX family may have different substrate specificity [93]. It has 
been suggested that LOX has the highest substrate specificity to collagen type I [106], 
whereas LOXL1 is essential for elastic fiber homeostasis [118]. Mice lacking LOXL1 
do not deposit normal elastic fibers and develop multiple organ disorders including 
vascular abnormalities with concomitant tropoelastin accumulation [118]. Mutations in 
the human gene for LOXL1 are associated with systemic elastic microfibrillopathy 
[119].  
Expression of LOXL2 has been observed in senescent fibroblasts and is associated with 
premature ageing [120]. The protein has also been found to be upregulated in several 
conditions characterized by liver fibrosis [101]. Like LOX itself, all four members of 
the LOX family have been implicated in the malignant transformation of various cell 
lines [101]. 
 
 Olga Ovchinnikova, 2010                                           Mechanisms behind plaque vulnerability 
 
32 
Table 2. Characteristics of the different members of the LOX family. Adapted from 
[93, 121].  
 
Family member 
 
Human 
chromosome 
 
Highest mRNA levels 
 
Similarity to 
LOX, % 
LOX 5q23 Aorta, heart, lung, kidney, skin, placenta 100 
LOXL1 15q24 Heart, placenta, skeletal muscle, lung, pancreas 85 
LOXL2 8p21 Fetal heart, prostate, uterus, placenta 58 
LOXL3 2p13 Brain, heart, uterus, aorta 65 
LOXL4 10q24 Placenta, lung, kidney, testis, pancreas, ovary 62 
 
 
5.4.2 Non-enzymatic collagen cross-linking  
AGE-related injury can promote the development of many age- and diabetes-related 
disorders, including atherosclerosis. It involves activation of growth factors and 
initiation of inflammatory reactions as well as enhancement of vascular stiffening, 
angiogenesis, and extracellular matrix accumulation [122].  
Collagen in the blood vessel wall has a relatively long biological half-life and with time 
undergoes significant non-enzymatic glycosylation (glycation). In contrast to the 
beneficial effects of the enzymatic collagen cross-links, non-enzymatic AGE cross-
links, such as pentosidine and glucosepane, deteriorate the biological and mechanical 
properties of tissues. The formation of AGE cross-links promotes fibrosis and decreases 
connective tissue flexibility, making them partly responsible for many fibrotic 
complications including atherosclerosis, especially in diabetic patients [122, 123]. 
Collagen glycation may impair collagen’s functional interaction with the cellular 
components within the vessel wall by modifying its binding to integrins [50].  
The chemistry of formation of AGE cross-links in collagen fibers somewhat resembles 
the mechanism of LOX-dependent cross-linking. However, it involves the formation of 
the aldehydes from glucose, ketose, or other metabolic intermediates. These aldehydes 
react with Lys or Hyl in collagen monomer to form a glycosyl-Lys via Schiff base 
formation. Such non-enzymatic cross-linking involves Lys or Hyl in helical domains of 
collagen monomer, but not in telopeptides. This distinguishes non-enzymatic collagen 
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cross-linking from enzymatic. Modified residues are stabilized by spontaneous 
Amadori rearrangement and further undergo reaction with Lys or arginine in adjacent 
collagen monomer to form irreversible inter-helical AGE cross-links [56, 124]. Such 
changes are accelerated in various diseases with a strong metabolic component, such as 
diabetes mellitus and end-stage renal disease [124].    
 
 
5.4.3 Extracellular cross-linking of collagen in atherosclerotic 
lesions (Papers I and III) 
In the vascular wall, the expression of LOX is restricted to fibrogenic SMCs. However 
cultured endothelial cells can also synthesize LOX [125]. The role of LOX in 
cardiovascular development and diseases has been studied mainly using animal models 
and cultured cells, and has mainly been focusing on the role of LOX in the 
development of aortic aneurysm [126, 127]. Inactivation of the Lox gene in mice results 
in fetal death due to a defective cardiovascular system including large aortic aneurysms 
caused by collagen and elastin abnormalities [128]. Animals on copper-deficient diets 
often die from aortic ruptures [129]. 
In humans, disorders in copper metabolism as seen in Menkes disease have been 
associated with a decreased activity of LOX and increased risk for development of 
myocardial infarction and abdominal aneurysm [130]. A clinical case of spontaneous 
coronary artery dissection due to a dramatic decrease in LOX levels and increased 
extracellular matrix disorganization has been reported recently [131].   
Very little attention has been given to the role of extracellular collagen maturation in 
determining the stability of atherosclerotic plaques. Earlier studies found increased 
LOX enzyme activity in the aortic lesions of atherosclerosis-prone rabbits and a 
significant increase in LOX mRNA expression in rat models of vascular restenosis. 
These observations could reflect accumulation of SMCs during lesion formation [132-
134].  
It is widely accepted that thinning and rupture of the fibrous cap of atherosclerotic 
lesions leads to thrombotic events that are more dangerous than artery occlusion [135]. 
It has been shown that systemic hypercholesterolemia downregulates LOX mRNA 
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expression in a porcine model of diet-induced atherosclerosis [136], and LOX and 
procollagen mRNA expression is reduced in the arterial wall of diabetic rats compared 
with controls [137].   
The lack of studies characterizing vascular LOX expression and function in 
atherogenesis stimulated us to address this question in murine and human 
atherosclerosis (Papers I and III).  
 
In paper I, we investigated how T cell-driven inflammation affects plaque morphology 
in Apoe-/- mice. We observed the reduction in amount of mature collagen in 
atherosclerotic plaques under hyperinflammatory conditions. Since we did not detect 
any differences in procollagen synthesis in these mice, we thought it would be relevant 
to study LOX. We detected LOX mRNA and active protein in aortae of 
hypercholesterolemic mice and found that enzyme expression was decreased in lesions 
with severe local inflammation and therefore, presumably, a more vulnerable 
phenotype (Figure 4A).    
In paper III, we investigated the role of LOX in human atherosclerosis and were able 
for the first time to localize LOX protein in human lesions. Predominant expression of 
LOX was observed in regions rich in collagen and SMCs in the fibrous cap and 
surrounding the necrotic core (Figure 4B). We, therefore, suggested that LOX may 
contribute to fibrous cap strengthening and necrotic core incapsulation given that LOX 
can induce SMCs migration [105, 108].  
Higher LOX mRNA and protein expression in human lesions was associated with a 
more stable phenotype of the plaque, because (1) LOX mRNA correlated significantly 
with mRNAs for procollagens, P4H and LH; and (2) the amount of active LOX protein 
positively correlated with the percentage of total collagen and with increased amounts 
of the mature enzymatic collagen cross-links (HP and LP) in atheromatas (Figure 4D). 
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Figure 4. (A) Active LOX protein was detected by western blotting in aortae of 12 week old 
(a12) and 18 week old (a18) Apoe-/- mice, and in mice with hyperinflamed plaques (T). (B) 
LOX protein was detected in human carotid lesions in the fibrous caps (filled arrow heads) and 
around necrotic areas (empty arrow head). Magnification x25. The round intensively stained 
structure is a section artifact. (C) Human carotid lesion stained with mouse immunoglobulins 
unspecific to LOX. (D) A positive correlation between active LOX and collagen cross-links in 
human atherosclerotic lesions as determined by the semi-quantitative western blot analysis of 
LOX and chromatographic analysis of collagen cross-links, respectively. HP- 
hydroxylysylpyridinolines, LP- lysylpyridinolines, TH-triple helix. 
 
Although recent in vitro studies suggest that LOX is expressed by endothelial cells and 
its downregulation is associated with endothelial dysfunction [125], we could not detect 
LOX positive endothelial cells overlying human atherosclerotic plaques. Instead, LOX 
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protein was localized in the immediate subendothelial space where it was co-localized 
with basement membrane collagen IV and with SMCs. Given that collagen IV is one of 
the substrates for LOX, we assumed that such subendothelial distribution of the enzyme 
helps to stabilize the endothelial layer by maintaining the integrity of the basement 
membranes.  
Decreased LOX-catalyzed collagen maturation in the media has been suggested as one 
of the mechanisms behind the development of abdominal aortic aneurysm [126, 128]. 
In paper III, we observed that LOX protein is lost from SMCs in the media below the 
atherosclerotic plaque. This may explain why atherosclerotic plaques grow outwards 
during their progression. 
Our data shows that LOX controls collagen maturation that is required for the structural 
integrity of the fibrous cap. Moreover, recent data further suggests anti-inflammatory 
properties of LOX, namely an ability to inhibit MCP-1 secretion from SMCs, thus 
preventing monocyte infiltration into vascular tissue [138]. Altogether, data suggests 
that increased LOX can be potentially beneficial to clinical outcomes of atherosclerosis. 
 
 
5.5 COLLAGEN DEGRADATION 
Mature collagen within the atherosclerotic plaque can be degraded by several families 
of matrix-degrading proteases. The most abundant proteases in the plaque are MMPs 
and cysteine proteases released by activated macrophages and mast cells [139-141]. 
Several members of these enzyme families have been found in vulnerable regions of 
atherosclerotic plaques and associated with clinical manifestations of acute vascular 
events and plaque progression [142-146].  
 
5.5.1 MMPs 
The family of zinc- and calcium-dependent MMPs consists of more than 20 structurally 
related proteases [40]. MMPs can be divided into five groups according to their 
substrate specificity: interstitial collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 
and -9), stromelysins (MMP-3, -10, -11 and -7), membrane type MMPs (MMP-14, -15, 
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-16 and -17) and others, including the metalloelastase MMP-12 [40]. Except for the 
membrane-type MMPs that are integrated in the plasma membrane, all MMPs are 
secreted into the extracellular space. Macrophages represent the major source of  
MMPs, but SMCs, endothelial cells, T cells and mast cells can also secrete a subset of 
this protease family [40].  
Almost half the members of the MMP family are present in the arterial wall [9, 140]. 
The interstitial collagenases, MMP-1, -8, -13, and -14, can efficiently degrade intact 
fibrillar collagens types I and III into 3/4 and 1/4 fragments which then become targets 
for other MMPs. The gelatinases, MMP-2 and -9, degrade mainly gelatin (denatured 
collagen) as well as nonfibrillar collagens, including type IV, and elastin. The 
stromelysins, MMP-3, -7, and -10, have a rather wide specificity [140]. Together 
MMPs can degrade practically all components of extracellular matrix found in plaques.  
The activity of MMPs is regulated at multiple levels including regulation of 
transcription, secretion, proteolytic activation of inactive proforms and inhibition by 
specific tissue inhibitors of MMPs (TIMP-1, -2, -3 and -4). All MMPs are effectively 
inhibited by forming 1:1 complexes with TIMPs [140].  
 
The role of MMPs in the process of plaque destabilization is rather controversial. On 
one hand, there is indirect evidence suggesting that macrophage derived MMPs in 
atheromata weaken the fibrous cap and promote disruption [9]. On the other hand, 
another line of evidence points to a plaque stabilizing role of certain MMPs due to their 
capacity to regulate SMC migration and proliferation; this should favor fibrous cap 
formation and repair after vascular injury [140]. Although functional genetic 
polymorphisms of some MMPs lead to increased prevalence of cardiovascular 
morbidity, the overall picture is still not consistent [12]. 
The collagenases MMP-1, -13, and -8 have been detected in vulnerable human 
atherosclerotic plaques and colocalized with cleaved collagen fragments in situ [143, 
146]. Numerous subsequent studies have localized MMP-2, -3,-7, -9, -11 and -12 to 
unstable and highly inflamed regions of human lesions, and correlated their high serum 
level with thrombotic complications [12, 40, 139].  
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However, it is very difficult to differentiate whether the level of MMPs is a cause or an 
effect of plaque destabilization. Increased local expression of proteases can simply 
reflect greater macrophage infiltration into the lesions [40]. The ability of MMPs to 
facilitate SMC migration to sites of injury can imply a beneficial role of MMPs in 
wound healing [29].  
Several animal studies support a plaque destabilizing potential of MMPs. Apoe-/- mice 
carrying a “knock-in” of a collagenase-resistant form of procollagen accumulates more 
collagen in their lesions than those with wild-type collagen [147]. Compound Apoe-/- x 
Mmp13-/- knockout mice show increased accumulation and maturation of collagen 
compared with Apoe-/- x Mmp-13+/+ counterparts [148]. MMP-14, a membrane-
associated MMP, also appears to contribute to collagenolysis and plaque destabilization 
in experimental atherosclerosis [149, 150].  
In contrast, Apoe-/- mice also deficient in MMP-2, -3, and -9 develop SMC-poor 
lesions in brachiocephalic arteries. Plaques in these mice show signs of possible 
ruptures as defined by a greater number of buried fibrous caps [149, 152]. Macrophage-
selective
 
overexpression of human MMP-1 in Apoe-/- mice leads to decreased lesion 
size [151]. Therefore, these MMPs were assumed to promote plaque stability. 
However, MMP-3 and -9 have harmful effects at atherosclerotic prone sites in aorta 
[153, 154]. Moreover, MMP-9 has differential effects on plaque progression at various 
stages of atherogenesis in mice. Overexpression of MMP-9 in advanced lesions leads to 
development of plaque with vulnerable morphology, whereas overexpression of MMP-
9 in early or intermediate lesions does not appear harmful [155].  
 
5.5.2 Cathepsins  
In addition to MMPs, certain cathepsins may contribute to plaque destabilization [57]. 
Cathepsins have potent elastolytic and collagenolytic activities [57]. Furthermore, 
cathepsin S has been implicated in the promoting of immune responses. The enzyme 
helps efficient antigen presentation by processing invariant chain of major 
histocompatibility complex (MHC) class II [156]. Finally, there is evidence that 
cathepsins proteolytically modify LDL and enhance the extracellular accumulation of 
LDL-derived lipid droplets within the arterial intima during atherogenesis [157].  
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The SMC-derived cathepsins S, K, L and F have been detected in human atheromata 
and localized to breaks in the elastic laminae [145, 157, 158]. Hyperlipidemic mice 
deficient for cathepsin S develop smaller lesions with better preserved elastin and 
decreased inflammation but reduced number of SMCs and collagen content [159]. 
Thus, it is possible that the cathepsins are important in promoting plaque destabilization 
primarily due to their capacity to initiate and maintain inflammation in the plaques and 
degrade elastin, whereas their effect on collagen metabolism within the fibrous cap is 
still questionable. 
 
In paper I, we investigated whether the degree of proteolytic degradation of collagen 
was increased in murine lesions with severe local inflammation and poor collagen 
quality. We analyzed several members of MMP and cathepsin families on the levels of 
mRNA, protein and proteolytic activity. We observed that only mRNA encoding 
MMP-13 and cathepsin S were increased under severe T cell-driven inflammation. 
mRNA for MMP-2, -3, -8, -12 and 14, TIMP-1, cathepsin K and L, and neutrophil 
elastase remained unchanged in mice with hyperinflammatory lesions when compared 
to controls (Figure 5A). The activity of proteolytic enzymes analyzed by gel 
zymography and the degree of collagen fragmentation did not change in mice with 
activated T cells. Instead we observed the reduction in LOX mRNA and protein as 
described earlier. Our study showed that T cell-driven inflammation mainly acts on 
LOX-dependent collagen maturation rather than on its degradation. Therefore, we 
suggest that the local environment within the atherosclerotic plaque may play a key role 
in a critical plaque weakening by providing more available collagen substrates to 
certain subsets of proteolytic enzymes.  
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5.6 CONCLUDING REMARKS: WHICH CAME FIRST, THE CHICKEN OR 
THE EGG?  
Collagens are not inert structures but are dynamic and multifaceted frameworks 
existing in atherosclerotic plaques. Collagen fibers accumulate at the onset of 
atherosclerosis, but eventually stabilize the fibrous cap preventing plaque rupture [160]. 
Clinically, patients are diagnosed with atherosclerosis at advanced stages of disease 
when lesions are established. Therapeutically, stabilization of the fibrous cap and thus 
prevention of plaque rupture are more relevant.  
It is believed that the weakening of the fibrous cap is caused by an imbalance between 
decreased collagen synthesis and increased collagen degradation [135]. However, 
broad-range synthetic inhibitors of MMPs are not used in preventive cardiological 
practice [40]. Moreover, animal models clearly suggest that specific proteases promote 
plaque stabilization, and the time course of atherogenesis is critical for the activation of 
some proteases [140, 155]. Mature, insoluble collagen is resistant to the majority of 
proteolytic enzymes and has specific cleavage sites only for collagenases [65]. 
Therefore, increased degradation of collagen fibers in the fibrous cap is not solely the 
causative factor in plaque rupture. 
We suggest that defective maturation of secreted collagen fibers contributes to the 
pathogenesis of plaque weakening. Previous studies demonstrate an abnormal 
biochemical composition and atypical organization of collagen in the fibrous cap [161]. 
These collagens are susceptible to fracture under stress. In addition, insufficient 
maturation of collagen fibers exposes additional MMP-cleavage sites which make 
collagen more susceptible to proteolytic degradation [65, 66].  
Collagen cross-linking catalyzed by LOX modulates the biomechanical properties of 
collagen [106]. Here, we demonstrate that LOX is active in murine and human 
atherosclerotic plaques, and its presence is associated with a stable plaque phenotype 
(Papers I and III). Hence, defective cross-linking because of low LOX activity could 
promote disorganization of the extracellular matrix in the fibrous cap. LOX inhibition 
shifts the balance of collagen to the immature soluble forms. These forms are prone to 
degradation by a broader spectrum of MMPs [66, 101, 106]. Therefore, the observed 
increase in collagen degradation in unstable atherosclerotic plaques may be a result of 
collagen fibers “vulnerability” upon LOX deficiency. 
 Olga Ovchinnikova, 2010                                           Mechanisms behind plaque vulnerability 
 
  41 
 
Immune mechanisms that regulate LOX-dependent collagen cross-linking in 
atherosclerotic plaques were evaluated and are presented in the chapter 6 of the thesis. 
Further investigation into these mechanisms would be helpful when developing new 
tools for diagnosis and prevention of the vascular complications of atherosclerosis.  
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6 REGULATION OF ATHEROSCLEROTIC PLAQUE 
STABILITY  
Sites of atherosclerotic plaque rupture are characterized by the presence of activated 
macrophages, T cells, and mast cells. These cells can affect the biosynthetic function of 
SMCs and collagen strength within the fibrous cap by producing pro-inflammatory 
cytokines and proteases [1]. SMCs can also interact with immune cells through direct 
cell-to-cell surface contacts, as seen with CD40L-CD40 ligation [162, 163].  
Cytokine networks within the atherosclerotic plaque are complex [164]. We focused on 
exploring cytokine regulation collagen biosynthesis in the fibrous cap. 
Collagen fiber formation may be controlled at several levels: (1) transcription and 
mRNA stability; (2) translation; (3) posttranslational modification; (4) intracellular and 
extracellular cross-linking and fiber deposition; and (5) degradation. Coordinated 
regulation of collagen synthesis and modification is critical in maintaining the integrity 
of the fibrous cap. 
Experiments in isolated cell culture systems have shown that many cytokines are 
capable of modulating collagen biosynthesis [93, 165, 166]. However, the complexity 
of the atherosclerotic plaque does not allow us to draw any firm conclusions based 
entirely on in vitro data. Out of the many cytokines present in the atheromata and those 
that control collagen biosynthesis, only some can influence the composition of the 
extracellular matrix in atherosclerotic lesions in animals [164]. Genetic and therapeutic 
manipulations in hyperlipidemic mice show that transforming growth factor (TGF)β 
[167] and osteoprotegerin (Paper II and III) are the most potent pro-fibrotic and 
plaque stabilizing agents, whereas interferon (IFN)γ [168, 169], interleukin (IL)-18 
[170-172] and IL-6 [173] promote plaque destabilization.   
Other factors - such as hypoxia, hyperlipidemia, and mechanical forces - can influence 
collagen production and maturation in atherosclerotic lesions [125, 160].   
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6.1 IMMUNOLOGICAL FACTORS AFFECTING PLAQUE STABILITY 
Activated T cells are present in atherosclerotic lesions at all stages of plaque 
development [10, 174]. CD4+ T cells and IFNγ, the cytokine produced in Th1 subset, 
exist in human atherosclerotic lesions and are associated with disease complications 
such as acute coronary syndrome [10, 175]. Regions of human atherosclerotic plaques 
that have ruptured are infiltrated with T cells [176]. Apoe-knockout mice that lack 
CD4+ cells (Apoe-/- x scid/scid mice) develop less atherosclerosis than their 
immunocompetent littermates and transfer of CD4+ T cells reverses this effect [177]. 
Uncontrolled T cell activation due to lack of TGFβ suppressive signaling leads to 
rampant inflammation and accelerated atherosclerosis in a hypercholesterolemic animal 
[178]. 
Th1 cells secrete IFN, which exerts its proatherogenic role by 1) stimulating 
expression of adhesive molecules in endothelial cells and promoting recruitment of T 
cells and macrophages to the plaques; 2) enhancing the efficiency of antigen-
presentation; and (3) increasing the production of pro-inflammatory cytokines and 
proteolytic enzymes in macrophages [179]. Exogenous treatment to Apoe-/- mice with 
IFN increases atherosclerosis [180]. In contrast, targeted gene deletions of IFNγ or its 
receptor lead to reduced atherosclerosis in the same animal model [168, 181].  
Apart from its proinflammatory properties, IFNγ can promote plaque destabilization by 
thinning the fibrous cap. The cytokine is a powerful inhibitor of SMC proliferation 
[182-184], and is capable of inhibiting basal as well as IL-1, PDGF, or TGFβ-
stimulated procollagen gene expression in SMCs [11]. Animal models have supported 
the antifibrotic effects of IFNγ. Apoe and IFNγ receptor double knockout mice show a 
reduction in atherosclerotic lesion size, but a marked increase in lesion collagen content 
[168]. Moreover, IFNγ can inhibit intimal thickening in the rat carotid balloon injury 
model [185, 186]. 
In human atherosclerotic plaques, expression of procollagen type I is negatively 
associated with the proximity of T cells [24]. Active T cells from patients with acute 
coronary syndrome can induce vascular SMC apoptosis via direct contact [187].  
Apart from inhibiting procollagen transcription, IFNγ affects enzymes important for 
posttranslational collagen maturation. Recombinant IFN attenuates P4H and LOX 
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gene expression and activity in cultured fibrogenic cells including vascular SMCs [188-
190].  
   
In paper I, we addressed the question of what mechanisms are involved in the T cell- 
mediated plaque vulnerability. We used the Apoe-/- mice, which express a dominant 
negative TGF receptor II under control of the CD4 promoter (Apoe-/- x CD4dnTβRII) 
[178]. In these mice, T cells produce a non-functional TGF receptor II, do not respond 
to anti-inflammatory TGF signaling and are markedly activated. This leads to 
increased production of proinflammatory cytokines, including 100-fold increase in 
INF mRNA in aortae.  
Apoe-/- x CD4dnTβRII mice develop advanced atherosclerotic lesions earlier than their 
Apoe-/- littermates [178] and, by the age of 15 weeks, they show signs of myocardial 
infarction (unpublished data), which suggests that lesions in these mice are more 
vulnerable. Indeed, histological analysis of lesions in the aortic roots revealed massive 
infiltration of macrophages and activated T cells and reduced collagen mass [178]. 
The lesions of Apoe-/- x CD4dnTβRII mice in paper I had increased amount of thin, 
immature fibers and decreased amount of thick mature fibers compared to lesion-size 
matched Apoe-/- controls. We, therefore, concluded that the collagen quality was 
impaired in the hyperinflamed lesions of these mice (Figure 5A). Surprisingly, the level 
of α-chain of procollagen I and III mRNA was not changed, and we could not detect 
any increase in collagen fragmentation in Apoe-/- x CD4dnTβRII mice. Instead, we 
observed that levels of LOX mRNA and protein were significantly reduced in aortae of 
Apoe-/- x CD4dnTβRII mice (Figure 5B). We also evaluated other factors involved in 
collagen maturation, namely P4H, LH and Hsp47. The effect of aggravated 
inflammation on expression of these molecules was not consistent. We hypothesize that 
the failure of extracellular LOX-dependent collagen maturation is a novel mechanism 
by which activated T cells may hamper plaque stability. 
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Figure 5. (A) Collagen composition in lesions of Apoe-/- x CD4dnTβRII mice and Apoe-/- 
controls. The graph shows the percentage of total collagen as well as areas of thick or thin 
fibers divided by lesion area. Morphometric analysis of micrographs stained with Picrosirius 
Red. (B) Aortic expression of mRNA for procollagen 1(I), LOX and collagen degrading 
enzymes in Apoe-/- x CD4dnTβRII mice. Results are presented as fold-change compared to 
Apoe-/- mice (dotted line). *P<0.05 versus control.  
 
Proinflammatory cytokines, such as IL-1β and TNF, and T cells via direct contact can 
activate macrophages to produce MMPs and cathepsins [40, 57, 139]. This suggests 
that inflammation can affect collagen metabolism by decreasing production of stable 
collagen fibers and increasing their degradation. In paper I, we observed that the effect 
of T cell-driven inflammation on collagen degradation was modest. Measurement of 
the gene expression profiles of proteolytic enzymes revealed that the hyperinflamed 
aortae overexpressed only MMP-13 and cathepsin S (Figure 5B). Cathepsin S protein 
expression was consistently increased. However, no increase in collagen fragmentation 
in aortae of mice with activated T cells was observed. Our results do not negate a 
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potentially important role for MMPs in plaque destabilization, rather, they supports the 
idea that T cells affect principally collagen maturation.  
In paper III we investigated whether T cell-driven inflammation can promote plaque 
vulnerability by reducing LOX-mediated collagen stabilization in human 
atherosclerosis. Gene expression patterns in human carotid plaques show that LOX 
mRNA expression correlates negatively to mRNA levels of several pro-inflammatory 
markers such as CD74, HLA-DR, lipocalin-2 and CD4 (Table 3). CD74 is the invariant 
chain associated intracellularly with HLA class II molecules and CD4 is the HLA class 
II co-receptor expressed on T cells. Both molecules are increased in inflamed regions of 
atherosclerotic plaques [1, 191]. Lipocalin-2, or neutrophil gelatinase-associated 
lipocalin (NGAL), is a glycoprotein found in neutrophil granules. It promotes MMP-9 
activation and localizes in regions of atherosclerotic plaques with high proteolytic 
activity [192]. Together, this data suggests that inflammation and proteolysis, 
conditions known to destabilize plaques, are associated with reduced LOX expression.  
 
Table 3. Correlation between mRNA levels of LOX and proinflammatory markers 
analyzed by gene expression arrays of human carotid plaques.  
Transcript Spearman rank correlation, rho p-value 
CD74 - 0.48 < 0.01 
HLA-DR - 0.44 < 0.01 
Lipocalin-2 - 0.31 < 0.01 
CD4 - 0.3 < 0.01 
RANKL - 0.26  NS 
INF- - 0.1 NS 
                NS indicates non-significant results 
 
Other factors can also facilitate fibrous cap weakening by decreasing collagen 
synthesis and cross-linking. Basic fibroblast growth factor inhibits collagen production 
and Hsp47 expression [82, 193, 194], and endothelial cell-derived nitric oxide reduces 
collagen production by cultured SMCs [195, 196].  
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Insulin-like growth factor-I inhibits mRNA for procollagens 1(I) and 1(III) and P4H 
activity in rats [197]. Administration of IL-18, a proinflammatory cytokine which 
induces IFNγ enhances atherogenesis and decreases plaque stability in Apoe-/- mice 
[172, 198]. IL-18 deficiency, in contrast, attenuates atherosclerosis progression and 
promotes plaque stability by increasing collagen deposition [170, 171].  
TNF and IL1β inhibit LOX expression and activity in cultured endothelial cells [199], 
SMCs [127] and in the vascular wall in rats [199]. In Apoe-/- mice, IL-6 deficiency 
reduces LOX mRNA levels and collagen content in atherosclerotic plaques [173]. 
Atherogenic concentrations of LDL and homocysteine, well-known risk factors for 
atherosclerosis, reduce LOX expression and activity in endothelial cells [136, 200]. 
Other condition related to collagen disorders is ascorbate deficiency, which hampers 
proline hydroxylation, causing scurvy, a disease characterized by reduced connective 
tissue strength and increased fragility of blood vessels [79]. Chronic vitamin C 
deficiency compromises collagen deposition in atherosclerotic lesions in Apoe-/- mice 
[80].  
 
In vivo evidence presented here supports findings from other studies and shows that 
LOX-dependent stabilization of collagen fibers can be hampered by proatherogenic 
stimuli in the atherosclerotic plaques. This can lead to plaque weakening and 
thrombotic events.  
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6.2 MEDIATORS WHICH SUPPORT PLAQUE STABILITY 
TGFβ is an anti-inflammatory, immunosuppressive cytokine [201], and is a powerful 
stimulator of collagen synthesis in vascular SMCs [11, 202, 203]. The promoter of the 
procollagen α1(I) gene bears a TGFβ activation element which suggests that TGFβ can 
influence collagen synthesis directly [204]. Neutralization of TGFβ in hyperlipidemic 
mice leads to formation of large atherosclerotic lesions with signs of active 
inflammation and decreased collagen content, supporting a critical role of TGFβ in 
matrix production and plaque stability [167, 205]. Patients with advanced 
atherosclerosis have markedly decreased serum levels of active TGFβ [206]. 
Stimulation of fibroblasts and vascular SMCs with TGF results in a significant 
increase in P4H, LH and LOX production and activity, implying that this growth factor 
can influence multiple steps of collagen biosynthesis [93, 188, 190, 207-210]. 
Consequently, absence of TGFβ signaling to vascular SMCs reduces mRNA expression 
and activity of LOX in mouse aortae, which leads to aneurysm formation [211].   
 
In papers II and III, we show that osteoprotegerin (OPG), a member of the tumor 
necrosis factor receptor superfamily, promotes atherosclerotic plaque stability in mice 
and humans by affecting SMC accumulation and LOX-dependent collagen maturation. 
A detailed description of the role of OPG in atherosclerosis progression and 
complications is given in the section 6.3 below. 
 
Among other mediators, PDGF enhances SMC migration, collagen production and 
LOX expression in vascular SMCs [108, 160, 212]. Similarly, granulocyte macrophage 
colony-stimulating factor can increase collagen content in atherosclerotic lesions and 
positively regulate LOX expression in vascular SMCs [213-215].  
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (statins) 
are believed to prevent plaque rupture through their lipid-lowering and pleotropic 
effects [216, 217]. Statins increase synthesis of procollagen type I in Apoe-/- mice 
[218], and abrogate the reduction of vascular LOX expression triggered by high levels 
of LDL in vivo and in vitro [219]. This data suggests that one of the pleotropic effects 
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of statin might be stabilization of the fibrous cap through an increase of enzymatic 
collagen maturation.   
Mechanical strain can stimulate collagen synthesis in cultured SMCs or ex vivo artery 
preparations which links local hemodynamic forces to plaque collagen production 
[160]. Furthermore, genes of procollagen, P4H and LOX are transcriptional targets of 
hypoxia-inducible factor 1α (HIF1α), which suggests that hypoxia is a strong regulator 
of fibrosis [220-222].  
 
6.3 THE RANK-RANKL-OPG AXIS IN PLAQUE STABILITY 
Receptor activator of nuclear factor-κB (RANK, TNFRSF11A), its ligand (RANKL, 
TNFSF11) and the decoy receptor for RANKL - osteoprotegerin (OPG, TNFRSF11B) 
- belong to proteins of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF) 
and Tumor Necrosis Factor Superfamily (TNFSF), and are associated with 
atherosclerosis development and plaque destabilization [223-225].   
OPG is a soluble decoy receptor for RANKL and prevents RANKL interaction with its 
transmembrane receptor – RANK [223]. OPG is a basic secretory glycoprotein with 7 
distinct structural domains. It can function as a 60 kDa monomer that has two 
apoptosis-mediating death domains and a heparin-binding region at the carboxyl 
terminal [225]. The formation of OPG homodimers is required for its binding to 
RANKL [226].  
The RANK-RANKL-OPG axis was initially recognized as a potent regulator of bone 
metabolism [227]. RANK is expressed on the surface of osteoclast precursors such as 
monocytes, macrophages, and dendritic cells. RANKL is expressed by osteoblasts, 
stromal cells and T cells. The RANK-RANKL interaction leads to osteoclast formation, 
fusion, differentiation, activation, and survival, leading to enhanced bone resorption 
[223, 227]. OPG, which also is produced from osteoblasts, serves to hamper this 
interaction and prevent bone loss. Mice lacking a functional Opg gene develop severe 
osteoporosis [228] and OPG administration effectively prevents bone resorption [229]. 
Opg-/- mice suffer from a profound calcification in the large arteries and partial aortic 
dissection [228], which suggests that OPG might be important in vascular pathology. 
 Olga Ovchinnikova, 2010                                           Mechanisms behind plaque vulnerability 
 
50 
Nevertheless, OPG’s impact in cardiovascular disease development remains unclear 
[224, 225, 230, 231]. It has been shown that OPG is present in the arterial wall in 
significant amounts [232]. Vascular SMCs and endothelial cells can produce OPG 
along with monocytes, T and B cells [233], and its release can be enhanced by 
stimulation with TNF or IL-1β [225]. OPG is expressed in healthy vessels as well as in 
atherosclerotic plaques [234]. Patients with neurological symptoms or acute coronary 
syndrome have elevated OPG expression compared to non-symptomatic cases [235, 
236]. Increased levels of OPG have been associated with increased risk for coronary 
artery disease, stroke and cardiovascular mortality not only in patients but also in the 
general population [224, 225, 230, 237, 238]. Epidemiological studies show a positive 
relationship between serum levels of OPG and prevalence and severity of coronary 
artery disease, cerebrovascular disease and peripheral vascular disease. Therefore, OPG 
was considered to be an independent risk factor for cardiovascular morbidity. However, 
it did not predict recurrent myocardial infarction in patients and failed to predict 
ischemic stroke in a healthy population [239, 240].  
Experimental evidence conflicts with these clinical findings. Mice lacking Opg develop 
significantly larger atherosclerotic lesions compared to Opg+/+ x Apoe-/- mice [241]. 
Administration of OPG to Ldlr-/- mice reduces calcification in the lesions, although it 
does not affect lesion size or the degree of inflammation [242]. In line with results from 
animal models, studies of functional genetic polymorphisms in humans show no 
association between polymorphisms in the promoter region of OPG gene with aortic 
calcification or coronary artery disease [243, 244]. This data further suggests that 
increased plasma OPG is perhaps a marker but not a mediator of adverse cardiovascular 
prognosis.  
 
In paper II, we investigated the effect of OPG administration on atherosclerosis 
development in Apoe-/- mice. Although OPG did not reduce plaque size and hamper 
inflammation in treated animals, it contributed to fibrous cap formation and lesion 
stabilization by promoting SMC accumulation and increasing collagen content. The 
increase in collagen content in lesions corresponded with elevated expression of LOX 
mRNA. This suggests that OPG is able to promote plaque stabilization by enhancing 
collagen cross-linking and strength (Figure 6). We showed also that administration of 
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recombinant murine OPG to cultured rat aortic SMCs significantly increased their 
proliferation. RANKL together with OPG did not affect the growth response. We 
suggest, therefore, that OPG impacts SMC growth and collagen matrix formation 
independently of RANKL. 
 
 
Figure 6. (A-E) Micrographs of immunohistochemical staining with an antibody against SMC 
marker SM-actin (A-B), and micrographs of sections stained with picrosirius red showing the 
collagen fiber composition (C-D) in atherosclerotic lesions of OPG- (A,C) and vehicle-treated 
mice (B,D). Note the cap-like structure in the lesion after OPG treatment (single arrow). The 
dashed line separates the intima from the media. (E) Area occupied by SM-actin+ SMCs or 
fibrous collagen expressed as % of total cross-section lesion area. *) p<0.05 vs. vehicle 
control. 
 
 
Following the plaque stabilizing role of OPG described in paper II, in paper III we 
focused on OPG role in human carotid plaques. Global gene array analysis in human 
carotid plaques showed that OPG mRNA expression correlated both positively to LOX 
mRNA expression (Figure 7A) and to the amount of SMCs in lesions. A significant 
positive correlation existed between serum levels of OPG and mature enzymatic 
collagen cross-links in the plaques (Figure 7B). In line with this, OPG treatment of 
cultured human aortic SMCs led to increased levels of procollagen type I gene. 
Therefore, we found further support for the notion that OPG may promote plaque 
stabilization by increasing collagen synthesis and LOX-dependent collagen maturation. 
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Figure 7. A significant positive correlation exists between mRNA expression of OPG and LOX 
according to gene array analysis of human carotid plaques (A); Serum levels of OPG correlate 
to the amount of mature enzymatic collagen cross-links in human carotid plaque samples (B).   
 
Epidemiological studies describing the potentially harmful role of OPG in 
atherosclerosis conflict with the related experimental evidence to date. A plausible 
explanation for this discrepancy may be that OPG exerts its protective action locally in 
the vasculature. OPG concentration in human arteries is at least 100 times higher than 
in plasma (our own unpublished data and [230]). Thus, high levels of OPG in serum 
can reflect on-going injuries to the vessel wall and possible “leakage” of OPG from the 
atherosclerotic plaque. Supporting this hypothesis, OPG in supernatants from 
endarterectomy explants from symptomatic patients is elevated [235]. Therefore, new 
experimental strategies to maintain OPG within atherosclerotic plaque where it may 
facilitate fibrous cap stability are warranted. 
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6.4 LEUKOTRIENES IN PLAQUE STABILITY 
Leukotrienes are lipid inflammatory and constrictive mediators derived from the 5-
lipoxygenase pathway of arachidonic acid metabolism [245]. Metabolites of the 5-
lipoxygenase pathway have strong proinflammatory activities in the cardiovascular 
system and thus may have an important role in atherogenesis. 
Enzyme 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP) initiate the 
metabolism of arachidonic acid from membrane phospholipids and lead to formation 
on an unstable precursor leukotriene (LT)A4. FLAP has no enzymatic activity, but 
stabilizes 5-LO and improves its interaction with the substrate [246]. LTA4 can be 
further metabolized on the same cells or can be transferred to the neighboring cells such 
as leucocytes, SMCs, endothelial cells or platelets [245, 247]. Further LT synthesis 
follows two distinct pathways: either hydrolyzation into LTB4, or conjugation with 
glutathione to form the cysteinyl-LT: LTC4, LTD4 and LTE4 (known as slow reacting 
substances of anaphylaxis) (Figure 8)[247].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The scheme of the metabolism of arachidonic acid through 5-lipoxygenase (5-LO) 
pathway. FLAP – 5-LO activating protein, LTA4H – LTA4 hydrolase, LTC4S – LTC4 synthase, 
BLT and CysLT – receptors for BLT4 and cysteinyl-LTs, respectively. Adapted from [247].      
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 LTs act in an autocrine/paracrine manner: LTB4 exerts its action via activation of G-
protein-coupled cell surface receptors, BLT1 and BLT2. Cysteinyl-LTs activate 
receptors CysLT1 and CysLT2 [247]. 
The 5-LO pathway is involved in atherosclerosis progression. Genetic studies on mice 
identified loci on chromosome 6 that are associated with reduced 5-LO expression and 
confer resistance to atherosclerosis in C57BL/6J and in Ldlr-/- mice [248-250]. 5-LO 
was found to be expressed in atherosclerotic lesions of Apoe-/- and Ldlr-/- mice 
colocalizing with macrophage-rich areas [250]. Furthermore, 5-LO, FLAP, LTA4 
hydrolase and BLT1 are significantly increased in human atherosclerotic lesions [251-
253]. Variations of 5-LO, FLAP and LTA4 hydrolase genes show association with 
cardiovascular disease and atherosclerotic complications such as myocardial infarction 
and stroke [254-257]. Compound Apoe-/- x Blt1-/- deficient mice develop smaller 
atherosclerotic lesions with decreased numbers of SMCs, macrophages and T cells 
[258, 259]. Administration of FLAP inhibitors to hyperlipidemic mice protects them 
from atherosclerosis [260]. Dual inhibition of cyclooxygenase and 5-LO not only 
reduces lesion size and degree of local inflammation in Ldlr-/- mice, but also stabilizes 
the plaque by increasing SMC number and collagen content, and reduces proteolytic 
activity in lesions [261]. However, there are studies that argue with the involvement of 
5-LO pathway in the pathogenesis of atherosclerosis [262].     
The role of LTB4 in atherosclerosis is defined by its ability to recruit inflammatory 
cells and to maintain immune activation within the atherosclerotic lesion [247]. LTB4 
exerts its action by stimulating BLT1 and BLT2 receptors on monocytes and T-cells, 
by upregulating chemokine production and by inducing nuclear factor (NF)-κB 
pathway [252, 258, 263]. LTB4 is thought to promote plaque vulnerability by 
increasing the activity of MMPs [263, 264]. In line with this, in diabetic patients 5-LO 
expression and LTB4 production are associated with increased levels of MMPs [265]. 
The role of LTB4 in collagen biosynthesis is unclear.  
 
In paper IV, we investigated the role of FLAP in atherosclerosis. Apoe-/- mouse model 
possessing T cells lacking TGFβ suppression (Apoe-/- x CD4dnTβRII mice) was used 
[178]. These mice provide the model with predominantly activated T cell-driven 
inflammation. In the aortae of these mice, FLAP gene expression, assessed by 
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microarray analysis, was significantly upregulated compared to Apoe-/- controls. A 2 to 
3- fold increase of FLAP mRNA in aortae, analyzed by quantitative real-time reverse-
transcription polymerase chain reaction (RT-PCR), and a significant elevation of FLAP 
protein in lesions of Apoe-/- x CD4dnTβRII mice were also observed. In lesions, FLAP 
co-localized with CD68+ macrophages but not with T cells. LTB4, a product of FLAP-
mediated reaction, was significantly elevated after ex vivo stimulation of aortae of 
Apoe-/- x CD4dnTβRII mice. As these mice have strongly activated T cells, it can be 
suggested that T cells increase FLAP expression and LTB4 production in macrophages 
in lesions. Supporting a proatherogenic role for FLAP, therapeutical inhibition of FLAP 
by administration of FLAP-inhibitor MK-886 significantly reduced atherosclerotic 
burden in Apoe-/- x CD4dnTβRII mice. Moreover, it decreased local inflammation 
defined by reduced number of T cells in the lesions and mRNA level for IFN in aortae 
of these mice.  
Therefore, the study suggests that the FLAP/LT signaling has an important role in 
adaptive immunological circuits in vascular inflammation. Activated by T cells 
macrophages increase their production of LTB4 via FLAP-mediated pathway. LTB4, in 
turn, recruits more T cells into lesions and maintain their activation by enhancing NFκB 
pathway [252].  
LOX expression and collagen maturation was impaired in mice with defective TGFβ 
signaling (paper I). Administration of a FLAP inhibitor failed to restore LOX and 
procollagen type I expression (unpublished data) (Figure 9), suggesting that metabolites 
of the 5-LO pathway do not influence collagen stability in atherosclerotic plaques. 
Instead, these molecules exert their action primarily by attracting more inflammatory 
cells into lesions and by promoting secretion and activation of collagen degrading 
enzymes.  
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Figure 9. Aortic mRNA expression of procollagen type I and LOX in Apoe-/- x CD4dnTβRII 
mice treated with either a FLAP-inhibitor (MK-886) or tylose as a control. Results are 
expressed as fold-change mRNA expression compared with tylose-treated animals. NS denotes 
non-significant results. 
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7 METHODOLOGICAL CONSIDERATIONS 
Our current understanding of atherosclerosis is based on molecular and biochemical 
evidence collected from animal models, cultured cells, human atherosclerotic lesions 
and from clinical as well as epidemiologic studies [1]. This thesis work encompasses all 
of these approaches to unravel the mechanisms causing plaque vulnerability. 
 
7.1 MOUSE MODELS 
Experiments in animals are needed to dissect the individual pathogenic steps and 
determine causality [1]. Under normal conditions laboratory mice do not develop 
atherosclerosis. Targeted deletion of the genes involved in lipid metabolism leads to 
severe hypercholesterolemia and spontaneous atherosclerosis [1]. Mice that lack 
apolipoprotein E (Apoe-/-) is an atherosclerosis-prone model used to study 
atherosclerosis [266]. Without a high-fat diet, these mice develop advanced 
atherosclerotic lesions already at the age of 18-weeks. We used these mice to study the 
effects of OPG injections in atherosclerosis development in paper II.  
The Apoe-/- mouse is also a widely used model for further genetic manipulations. By 
mating these mice with knockout mice lacking immunoregulatory genes, it is possible 
to clarify the role of immunologic and inflammatory mechanisms in atherosclerosis 
[266]. A mouse strain that has a dominant negative TGF-β receptor under the CD4 
promoter exists and is useful because these mice have T cells which produce non-
functional TGFβ receptor and do not respond to anti-inflammatory TGFβ signaling 
[267]. This leads to an accelerated activation of T cells and increased production of 
INFγ. These mice were crossed with the Apoe knockout mouse strain to specifically 
address the role of TGFβ in atherosclerosis (Apoe-/- x CD4dnTβRII mice) [178]. 
Lesions of Apoe-/- x CD4dnTβRII mice display increased macrophage infiltration and 
MHC class II expression on cells which reflects elevated local INFγ production. Thus, 
we can investigate the effects of unsuppressed T cell-driven inflammation on plaque 
progression. We used Apoe-/- x CD4dnTβRII mice in papers I and IV.  
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7.2 HUMAN BIOBANKS (BIKE, SPICE) 
Experimental evidence derived from non-human animal models must be validated by 
testing in humans or on human biological samples.  Therefore, we analyzed human 
atherosclerotic plaques from two biobanks of carotid endarterectomies generated in 
Karolinska University Hospital, Stockholm, Sweden, and Almazov Federal Heart, 
Blood and Endocrinology Center and City Hospital #2, St. Petersburg, Russia. Upon 
informed consent, atherosclerotic plaques from carotid arteries were retrieved from 
patients during carotid endarterectomies. This biological material was stored frozen 
with the intent to be used for future research projects which would carry out molecular 
and biochemical strategies. Patient data and biographies were also collected.   
The Biobank of Karolinska Carotid Endarterectomies (BiKE) was established in 2003 
in collaboration between the Department of Vascular Surgery and the Cardiovascular 
Research laboratories at the Center for Molecular Medicine at Karolinska University 
Hospital [253, 268-270]. BiKE currently contains more than 450 atherosclerotic 
lesions. The Biobank of St. Petersburg Investigation of Carotid Endarterectomies 
(SPICE) was started in 2005 as a part of the collaboration between Karolinska Institutet 
and Almazov Federal Heart, Blood and Endocrinology Center (Table 4). SPICE 
contains more than 100 patients. Its clinical database is currently under development. 
 
Table 4. General characterization of patients from biobanks BiKE and SPICE. 
 
Parameters 
Values 
BiKE SPICE 
Number of patients 107 144 
Male / Female  76.1% / 23.9 79% / 21%  
Age, years (mean ± SD) 71.37 ± 8.61 62 ± 8.1 
 
 
 Pharmacological treatment:      
Antiplatelet agents   32.6% 80% 
Statins  21% 38% 
Angiotensin converting enzyme inhibitors  25.4% 58% 
β-blockers  46.4% 53% 
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RNA from 144 human carotid endarterectomies from BiKE was analyzed by real-time 
RT-PCR (paper III). Total gene expression profiling was performed on 69 RNA 
samples from the same cohort, using Affymetrix Gene Array U133 Plus 2.0. The 
samples were hybridized and scanned at the Karolinska Institute Affymetrix core 
facility; obtained cel-files were pre-processed and log2-transformed using RMA-
normalization. Frozen sections, protein extracts, and serum from 24 human carotid 
endarterectomies from SPICE were also included. 
 
A limitation in this study is the lack of an ideal mouse model or method to investigate 
plaque vulnerability. Human lesion samples are healed after the rupture and markers 
and mediators in these events are captured after the incident. Collagen composition is 
an important factor that protects the plaque against rupture. Therefore, we aimed to 
assess inflammatory mediators in collagen dynamics by using animal models and 
validated these mechanisms using human biological samples.  Overlaying these two 
approaches can model how plaque stability is regulated in humans.   
 
7.3 COLLAGEN ANALYSIS 
Collagen content in tissues can be analyzed by histological techniques and biochemical 
methods. Apart from immunostaining against individual collagen types, histological 
staining using different dyes can be used. Traditional staining of fibrous tissues such as 
van Gieson and the various forms of trichrome are limiting. They do not stain thin 
collagen fibers [271, 272]. Picrosirius red binds
 
specifically to collagen and stains all 
different collagen fibers including thin ones. The method can be powered by 
microscopic examination of stained tissues under polarized light, which allows the 
generation of high-contrast images of the collagenous skeleton in tissues including 
atherosclerotic plaques. A fundamental physical property of collagen fibers, its natural 
birefringence, favors the use of Picrosirius red method over other staining techniques. 
Due to its anisotropic properties, collagen fibers appear bright when viewed with 
polarized light. Picrosirius red dye also has an anisotropic molecular organization and 
when bound to collagen in an ordered manner, it enhances collagen birefringence [272]. 
The intensity of birefringence depends on thickness and orientation of fibers. Well 
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organized, thick and tightly packed collagen fibers retard the linear polarized light 
passing though the tissue. Such fibers appear much brighter and have bright orange-red 
colors (Figure 10). Thin and poorly packed fibers appear less bright and have a green 
color [273]. Finally, the method also helps to avoid identification of non-collagenous 
proteins such as proteoglycans and fibronectin [271]. We used the method in papers I, 
II, III. 
 
 
 
 
Figure 10. Micrograph presents a sample of 
human carotid plaque stained with Picrosirius 
red and visualized under polarized light. 
Magnification x100. 
 
 
 A limitation to the Picrosirius red method is that it does not allow distinguishing, non-
reducible, enzymatic cross-links from non-enzymatic cross-links.  This makes it 
unsuitable for analyzing collagen quality in complex, highly inflamed tissues, such as 
human atherosclerotic plaques. Therefore, in paper III we complemented the 
histological examination of collagen with biochemical analysis of different mature 
collagen cross-links. A high-performance liquid chromatographic assay of tissue 
extracts allows differentiated analysis of enzymatic cross-links such as 
hydroxylysylpyridinoline (HP) and lysyl-pyridinoline (LP), and non-enzymatic cross-
links such as pentosidine. The cross-links are detected due to their native fluorescence. 
The quantities of each cross-link can be then expressed as the number of residues per 
collagen chain, assuming 300 hydroxyproline residues per triple helix given that the 
prolyl hydroxylation level in collagen is stable [274].        
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8 Quality matters: CONCLUDING REMARKS  
The existing paradigm states that activated inflammatory cells in the plaques cause 
fibrous cap weakening by shifting the balance toward increased proteolytic degradation 
of collagen fibers. This thesis presents a new understanding to this concept. The 
strength of the fibrous cap does not only depend on the amount of collagen, but also on 
the efficiency of fiber cross-linking generated in complex multistep process of collagen 
maturation  Proinflammatory mediators inhibit posttranslational maturation of collagen 
which leads to collagen fragility and reduce its resistance to proteolytic attacks and 
hemodynamic strain. 
In paper I, T cell-driven inflammation reduces expression of LOX, the enzyme 
essential for collagen cross-linking.  This results in a disorganization of collagen fibers 
in atherosclerotic lesions of Apoe-/- x CD4dnTβRII mice. In paper II, OPG treatment 
to Apoe knockout mice stabilized atherosclerotic lesions by promoting SMC 
accumulation, LOX-dependent collagen cross-linking and development of fibrous caps. 
In paper III, using human carotid atherosclerotic plaques, LOX protein was localized 
in the fibrous cap and perinecrotic regions. These areas contained both collagen and 
SMCs. A higher LOX mRNA and protein were associated with a more stable 
phenotype of the plaques. Examination of gene expression in plaques revealed a 
positive correlation between LOX and OPG and a negative correlation between LOX 
and markers of inflammation. In paper IV, activated Th1 cells in atherosclerotic 
plaques of Apoe-/- x CD4dnTβRII mice increased production of a lipid mediator, 
LTB4, in macrophages by enhancing 5-LO-mediated pathway. Secretion of LTB4 by 
macrophages could influence T cells by recruiting more T cells into lesions and 
activating NFκB pathway. Pharmaceutical FLAP inhibition provided a possible 
therapeutic tool to stabilize the plaque by reducing local inflammation. However, it did 
not have any significant effect on collagen synthesis.  
A summary of the findings presented in this thesis is in Figure 11. Mechanisms that 
influence the stability of the atherosclerotic plaque are depicted here. The stability of 
the atherosclerotic plaque depends on the mechanical properties of collagen fibers in 
the fibrous cap. LOX catalyzes the extracellular cross-linking of fibrillar collagens and 
mediates their thermal and mechanical stability. Sufficient extracellular maturation of 
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collagen by LOX is important to maintain the stability of the collagen-rich fibrous cap. 
Catalyzing the formation of cross-links in the basement membrane collagen IV, LOX 
supports the integrity of the endothelial layer. Finally, LOX stabilizes the plaque by 
inducing the migration of SMCs to the fibrous cap and to perinecrotic regions of the 
plaques (Paper III). 
Collagen fiber stability depends on the balance between proinflammatory and anti-
inflammatory stimuli in the atherosclerotic plaque. Activated Th1 cells produce IFN 
and promote the development of a highly inflammatory microenvironment in the 
fibrous cap by activating adjacent cells. This leads to decreased secretion of 
procollagen and reduced production of LOX (Paper I and III). Insufficient cross-
linking of collagen makes it “vulnerable”. Weak fibers cannot resist hemodymanic 
strain and are more prone to proteolytic degradation. Collagen-degrading proteases 
have better access to cleavage sites of loose-packed collagen fibers and degrade them 
more efficiently. All these lead to fibrous cap weakening and eventually to plaque 
rupture. 
Activated by Th1 cells, macrophages produce proinflammatory mediators, including 
LTB4 that sustains the proinflammatory cascade within the atherosclerotic plaque 
(Paper IV). LTB4 is capable of inducing MMPs production in macrophages in an 
autocrine/paracrine manner.             
The impact of proinflammatory mediators is balanced by anti-inflammatory, profibrotic 
agents, such as OPG, that is produced by SMCs and endothelial cells in the lesion. 
OPG can increase proliferation and induce collagen synthesis in SMCs (Paper II and 
III). OPG can also induce production of LOX, which promotes stabilization of newly 
secreted collagen fibers. 
In summary, this thesis presents novel evidence showing that LOX-dependent 
collagen cross-linking has an important role in the stabilization of the atherosclerotic 
plaques. Cross-linked collagen fibers have higher tensile strength, which reduces the 
risk for the fibrous cap rupture and thrombotic events. The process of collagen 
maturation is regulated by pro- and anti-inflammatory mediators within the 
atherosclerotic plaque. The evidence presented here, for the first time, offers a new 
understanding to the impact of immunological mediators in development of myocardial 
infarction and stroke, and provides potential targets for plaque stabilization therapy.  
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